264 related articles for article (PubMed ID: 30922960)
1. Aberrations in DNA repair pathways in cancer and therapeutic significances.
Motegi A; Masutani M; Yoshioka KI; Bessho T
Semin Cancer Biol; 2019 Oct; 58():29-46. PubMed ID: 30922960
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribosyl)ation in carcinogenesis.
Masutani M; Fujimori H
Mol Aspects Med; 2013 Dec; 34(6):1202-16. PubMed ID: 23714734
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
4. Exploiting DNA repair defects in colorectal cancer.
Reilly NM; Novara L; Di Nicolantonio F; Bardelli A
Mol Oncol; 2019 Apr; 13(4):681-700. PubMed ID: 30714316
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
6. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
7. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
Cipak L; Jantova S
Neoplasma; 2010; 57(5):401-5. PubMed ID: 20568893
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
9. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Chroma K; Mistrik M; Moudry P; Gursky J; Liptay M; Strauss R; Skrott Z; Vrtel R; Bartkova J; Kramara J; Bartek J
Oncogene; 2017 Apr; 36(17):2405-2422. PubMed ID: 27841863
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
[TBL] [Abstract][Full Text] [Related]
11. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
12. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
13. Drugging the Cancers Addicted to DNA Repair.
Nickoloff JA; Jones D; Lee SH; Williamson EA; Hromas R
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 28521333
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA damage response in cancer therapy.
Hosoya N; Miyagawa K
Cancer Sci; 2014 Apr; 105(4):370-88. PubMed ID: 24484288
[TBL] [Abstract][Full Text] [Related]
15. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy.
Silva SB; Wanderley CWS; Colli LM
Front Immunol; 2022; 13():826577. PubMed ID: 35211121
[TBL] [Abstract][Full Text] [Related]
17. Strategies for targeting the DNA damage response for cancer therapeutics.
Zhang D; Wang HB; Brinkman KL; Han SX; Xu B
Chin J Cancer; 2012 Aug; 31(8):359-63. PubMed ID: 22704491
[TBL] [Abstract][Full Text] [Related]
18. [DNA repair pathways and non-small cell lung cancer: clinical perspectives].
Olaussen KA; Planchard D; Adam J; Soria JC
Bull Cancer; 2011 Mar; 98(3):305-22. PubMed ID: 21459711
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
20. Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.
O'Kane GM; Connor AA; Gallinger S
Trends Mol Med; 2017 Dec; 23(12):1121-1137. PubMed ID: 29133135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
